Agreement marks achievement of Cerenome’s full-year 2026 commercial payer coverage objective for CNSide HOUSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed…